Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04784247 · ClinicalTrials.gov registry record · Phase 2
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
A Phase 2 study of Advanced Sarcoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 7
- Study locations
NCT04784247 is a Phase 2 study of Advanced Sarcoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 52 participants. The trial reports 7 study locations across 2 states.
The verdict
NCT04784247, a Phase 2 study of Advanced Sarcoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Lenvatinib
Study Locations (7)
New York
- Memorial Sloan Kettering Cancer Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-18 |
| Est. Completion | 2026-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04784247
The ClinicalTrials.gov registry entry for NCT04784247 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Sarcoma appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04784247 reports 7 study locations spanning 2 distinct geographic areas - top geographies include New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT04784247 about?
NCT04784247 is a clinical study titled "Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma". The purpose of this study is to find out whether combining the study drugs, lenvatinib and pembrolizumab, is a safe and effective treatment for metastatic soft tissue sarcomas that cannot be removed with surgery.
What is the current status of trial NCT04784247?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2021-03-18. Estimated completion is 2026-03.
What conditions does trial NCT04784247 study?
This clinical trial studies the following conditions: Advanced Sarcoma.
What interventions are being tested in trial NCT04784247?
The interventions under investigation include: Pembrolizumab (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT04784247?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04784247 being conducted?
This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.